Blog
Credibly reintermediate backend ideas for cross-platform models. Continually reintermediate integrated processes through technically sound intellectual capital.
21 November, 2023 NewsInvestigationNews
Seguimos avanzando en investigación. Nuestro Instituto ha recibido su primera patente para el desarrollo de tratamientos con células mesenquimales.
Los productos medicinales de terapia avanzada son una nueva generación de productos terapéuticos para el tratamiento efectivo de enfermedades complejas y de alto impacto. La Unidad de Terapias Avanzadas (UTA) del IDCBIS viene liderando el avance de este importante campo de la biotecnología a partir de la implementación de capacidades científicas y tecnológicas para generar medicinas mas costo-efectivas que resuelvan problemas específicos en salud de la población.
En este proceso, la UTA desarrolla diferentes innovaciones que incluyen nuevos métodos para la producción biofarmacéutica de productos de terapia avanzada, que en la actualidad se encuentran en procesos de protección intelectual. En ese sentido la Superintendencia de Industria y Comercio concedió la primera patente al IDCBIS denominada “Método de estimulación de células estromales mesenquimales para inducir expresión de factores inmunomoduladores”, una tecnología desarrollada por investigadores de la UTA.
Con esta tecnología se pueden generar productos medicinales para tratar enfermedades que por su componente altamente inflamatorio, causan la degeneración y pérdida de función de diferentes tejidos y órganos. La patente concede la propiedad al IDCBIS sobre una nueva metodología para la producción de este tipo de medicamentos a partir de la potenciación del efecto antiinflamatorio de células estromales mesenquimales, como principio activo de estos nuevos medicamentos biotecnológicos.
Con este logro, el IDCBIS se posiciona en el sector de investigación e innovación biotecnológico como centro de desarrollo de terapias avanzadas para el servicio del sector salud en el Distrito y el país.
Colombia se encuentra en el umbral de un emocionante avance en la medicina y la atención médica con el lanzamiento del proyecto pionero “Donantes Únicos”. Este innovador programa tiene como objetivo abordar la crítica necesidad de sangre con grupos sanguíneos poco comunes, que en el pasado ha requerido importaciones internacionales y ha resultado en complicaciones clínicas graves para pacientes en situaciones críticas.
La escasez de grupos sanguíneos poco comunes ha sido un desafío persistente en el ámbito médico colombiano, obligando en ocasiones a importar sangre desde otros países, como el caso notorio de Medellín, que ha recurrido a componentes sanguíneos de Brasil. Esto ha llevado a situaciones donde se han realizado transfusiones de sangre incompatible, con consecuencias graves para los pacientes.
Para el Dr. Bernardo Camacho, director del IDCBIS, “Este proyecto de ‘Donantes Únicos’ es pionero en América Latina y nuestro instituto se convierte en un centro de referencia para la investigación científica que es el propósito de esta administración de apoyar la ciencia con recursos propios y con el sistema de regalías”.
Este proyecto revolucionario aborda de manera innovadora y prometedora, dos componentes claves:
Identificación de Donantes Fidelizados: El programa busca establecer un grupo de donantes fidelizados que estén disponibles de inmediato cuando se necesite una donación para pacientes con grupos sanguíneos poco comunes. Esto asegurará un acceso rápido y seguro a las transfusiones necesarias, reduciendo las complicaciones médicas.
Criopreservación de Glóbulos Rojos: Una parte revolucionaria del proyecto es la criopreservación de unidades de glóbulos rojos, lo que extenderá significativamente su vida útil de 42 días a casi 10 años. Este inventario de sangre criopreservada permitirá un suministro sostenible y confiable para pacientes con fenotipos raros en Colombia.
“La iniciativa que está teniendo el IDCBIS, para que su banco de sangre cuente con tipologías diferentes o extrañas, es bien interesante y útil ya que va ayudar a muchas familias como la mía, donde prima salvar vidas”. Afirmó, Jairo Fandiño, donante de sangre.
Alcance Nacional y Colaboración Internacional
Un aspecto crucial del proyecto es su alcance nacional. Se espera que cualquier entidad dentro de la red nacional de sangre pueda acceder al programa “Donantes Únicos” para buscar grupos sanguíneos poco comunes cuando sea necesario. Si las unidades criopreservadas están disponibles en el IDCBIS, se podrán suministrar de inmediato. En casos donde no haya donantes disponibles en Colombia, el proyecto se conectará con redes colaborativas a nivel internacional para obtener la sangre necesaria.
Este proyecto innovador representa un gran avance en la atención médica en Colombia y ofrece esperanza a los pacientes con grupos sanguíneos poco comunes. “Donantes Únicos” no solo garantizará la disponibilidad de sangre crítica en momentos cruciales, sino que también contribuirá a reducir las complicaciones médicas y salvar vidas.
21 July, 2023 DonaciónAgreementsInvestigationNewsNewsAwards
¡Buenas noticias para Bogotá y toda Colombia! El Banco Distrital de Sangre del IDCBIS ha obtenido la certificación más prestigiosa en calidad para los bancos de sangre a nivel internacional. La Fundación CAT, reconocida entidad de certificación en transfusión, terapia celular y tisular de España, ha otorgado a esta institución de salud una acreditación que garantiza la excelencia en sus prestaciones médicas.
Este logro trascendental coloca al Banco Distrital de Sangre IDCBIS en un lugar destacado no solo a nivel nacional, sino también como referente internacional en bancos de sangre y servicios de transfusión. Nuestra entidad ha demostrado su compromiso inquebrantable con la calidad y la seguridad al ser el único banco en el país que realiza pruebas de biología molecular (NAT) al 100% de los componentes sanguíneos para garantizar la seguridad en las transfusiones.
La acreditación CAT, que se renueva cada cuatro años, destaca la excelencia en medicina transfusional que el Banco Distrital de Sangre IDCBIS ofrece a la sociedad. Tanto los donantes como los pacientes que reciben los hemocomponentes de este banco se benefician de la seguridad y calidad garantizada por esta certificación.
El Dr. Bernardo Camacho, director del IDCBIS, expresó su satisfacción al recibir la noticia: “Nos complace anunciar a la comunidad científica, académica, sanitaria y a la sociedad, la obtención de esta certificación internacional en calidad para nuestro Banco Distrital de Sangre. Cumplimos con los más altos estándares de calidad europeos en la captación, procesamiento y distribución de los hemocomponentes”.
Esta certificación no solo enaltece al Banco Distrital de Sangre IDCBIS, sino que también posiciona a Bogotá como un referente en calidad en medicina transfusional, generando reconocimiento y confianza en los productos y servicios de salud ofrecidos a la población. El compromiso de nuestra institución con la seguridad y calidad de las donaciones es evidente en sus estrictos protocolos y estándares internacionales, lo que garantiza que cada donante experimente un proceso seguro y cómodo.
Le puede interesar: Una donación, cuatro bebés beneficiados
Con este logro, los pacientes que dependen de transfusiones sanguíneas pueden tener la tranquilidad de recibir componentes de la más alta calidad y seguridad.
En resumen, el Banco Distrital de Sangre IDCBIS ha alcanzado un hito excepcional al obtener la certificación CAT, consolidando su liderazgo en la medicina transfusional y proyectando a Bogotá como una ciudad comprometida con la excelencia en el cuidado de la salud de sus ciudadanos. Esta noticia nos llena de orgullo y confianza en el sistema de salud de nuestra ciudad y país.
¡Felicidades al Banco Distrital de Sangre IDCBIS por este logro sobresaliente en beneficio de toda la comunidad!
6 September, 2022 AgreementsNewsof Tissue
The District Tissue Bank of the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) has established itself as a reference bank in Latin America, training health professionals from different countries of the continent, this time the turn was for Chile.
August 26, 2022. The tissue bank of Iquique, Chile, is developing a project that arises from the need of skin allografts for the management of burn patients. In Chile, on average there is only one skin donor in the country per year, therefore, the availability of cadaveric donor skin for transplantation is almost null. This opened the need for the use of living donor skin from body contouring surgeries.
In order to improve, grow and have the standards that a tissue bank requires, doctors Aldo Cañete, children's surgeon and director of the Regional Skin and Tissue Bank; Luana Mandriaza, coordinator of the Regional Bank; Jennifer Gómez, nurse in charge of organ and tissue procurement; María José Pulgar, nurse coordinator of the skin program and Dr. Marcelo Fonseca, plastic surgeon, arrived in Bogotá on August. Marcelo Fonseca, plastic surgeon, arrived in Bogota on August 22 and during their visit they have been trained in the processes of rescue, processing and quality management of lamellar tissue, skin, amniotic membrane and acellular dermis at the IDCBIS District Tissue Bank.
During their visit, the professionals of the Tissue Bank of Iquique attended the Burn Unit of the Simon Bolivar Hospital, as a referral in the integral treatment of the burned patient.
The District Tissue Bank of the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) is the only multipurpose public bank in the country and the first in Latin America with development and standardization in acellular dermis to favor the regeneration of definitive skin in burn patients. The Bank has INVIMA certification in good practices for ocular, musculoskeletal and skin tissue, in addition to being pioneers in Colombia in the amniotic membrane donation program, tissue that is used for the treatment of burn patients and for ophthalmology and maxillofacial surgery specialties.
"This knowledge that IDCBIS has given us will help our patients in Chile, since we are the only ones who process skin and we will be able to perfect our processes to improve the quality of life of many people," said Dr. Marcelo Fonseca, plastic surgeon.
This referral visit was possible thanks to the willingness of the Bank's staff headed by the director of IDCBIS, Dr. Bernardo Camacho, who has been leading international cooperation agreements that allow the consolidation of a scientific and medical community in the country and the region around research and altruism of citizenship.
30 August, 2022 AgreementsNewsof Tissue
The District Tissue Bank IDCBIS will donate the skin to attend burn patients in the Mantanzas region of Cuba.
August 19, 2022. On August 5, in the province of Matanzas, Cuba, a fire broke out in an industrial zone due to a lightning strike in an oil storage facility, which caused the conflagration, leaving more than 60 people injured with burns.
The District Tissue Bank IDCBIS, an entity linked to the District Health Secretariat, as humanitarian aid has donated 3 thousand cm2 of skin to the Cuban Government to help in the recovery of the wounded from the massive fire that occurred in this country.
The donation was made thanks to the efforts of the Colombian Ministry of Health in alliance with the Cuban Vice-Ministry of Health, the Cuban Ambassador to Colombia and the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) linked to the District Health Secretariat of Bogota.
The Director of IDCBIS, Bernardo Camacho, stated that "in addition to expressing the generosity and international solidarity of this donation with the tragedy, it is the recognition of the high quality and trust in the IDCBIS District Tissue Bank to distribute to burn patients who need this tissue for their recovery. These tissues were rescued from Colombian donors, complying with all safety and quality standards for the care of patients who require it."
The IDCBIS currently has the only multipurpose Tissue Bank in the country, which favors access to the most vulnerable population with transplant requirements and has the selection of donors, rescue, processing, preservation, storage and distribution of human tissues with high quality standards. It is the only multipurpose bank in the country and the first in Latin America with development and standardization in acellular dermis to improve the regeneration of definitive skin in burn patients.
The Bank processes cornea and sclera, skin, musculoskeletal tissue and amniotic membrane for use in ophthalmology, plastic surgery and maxillofacial surgery.
Media coverage
Telesur: Colombia donates skin for burned patients of the fire in Cuba
El Colombiano: Colombia joins humanitarian aid to Cuba: will donate skin for the injured in Matanzas
About the District Tissue Bank
17 June, 2022 InvestigationNewsAwardsUncategorized
The institute has been recognized for meeting very strict criteria, as well as for its advances in research.
Note originally published in: ediciónmedica.com
The District Institute of Science, Biotechnology and Innovation in Health (IDCBIS), has informed the entire community, both scientific and academic, that the Transfusion, Tissue and Cellular Medicine Research Group (GIMTTYC) has obtained the classification of "Transfusion, Tissue and Cellular Medicine" group. A1 research by the Ministry of Science, Technology and Innovation.
It should be noted that the group GIMTTYC is an interdisciplinary group with actions aimed at the development of three main areas in health: transfusion medicine, tissue and cellular therapy.
Its objective has been to identify health problems in the areas of transfusion medicine, tissue and cellular therapy in order to contribute in the solution through the development of research projects based on ethical criteria, that generate new knowledge, strengthen the training of researchers and consolidate research networks.
In interview with MEDICAL EDITION, Bernardo Camacho, director of the IDCBIS, said that "in the last call for applications more than 7,000 research groupsThe application is very rigorous, but in the end, a small group obtained the recognition, 849 groups remained".
Camacho explained that, "in group A there are 1,174, in group B there are 1,830 and in group C there are 2,376 groups. The A group has the least number of groups, but there are still 531 recognized groups."He added that "the A1 group is for research, which is like the top, in the sense that it is required to rigorously comply with the criteria to be in this group".
"In our case for the last four years we were in group C, but now we go up to A1 this is due to several factors, firstly having a senior researcher, international, scientific publications in high impact indexed journals," Camacho pointed out.
"For us that was very important because we were recognized in the field of health sciences, but we specifically have a research focus in the area of advanced cell therapies, among others. So we were recognized because we have carried out a great deal of scientific research and even original research in the focus that we have," said Camacho.
The director also explained that they train master's and doctoral students, and also have associate and senior researchers. "We are implementing the inclusion of more senior researchers."
"That designation is earned by all the achievements that the research group has made, but in October of the previous year we were recognized as a research center for the next five years, this due to the strength in information and scientific production, which performs the team of scientists who are working with us," Camacho has pointed out.
17 March, 2022 DonaciónInvestigationNews
The IDCBIS research team plans to start clinical trials by the end of 2022.
January, 2022. Currently, the recovery time for fractures can take from 3 to 6 months. However, in some particular conditions, this time is extended to a year or more, because a large number of surgeries are required for patients to recover their mobility and normal rhythm of life. For this reason, researchers at the Tissue Engineering Unit of the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) decided to use 3D printing to develop bone structures that can be applied in general and personalized medicine.
This is the first time that design, 3D printing and basic sciences have been combined to develop a device made with polylactic acid (PLA) for the repair of musculoskeletal tissue in Colombia. The results obtained in preclinical trials have shown greater efficacy compared to conventional methods. This is due to the device's architecture, which favors cell migration and its design prevents the muscle from invading it, thus contributing to tissue repair.
This research is led by scientists Ingrid Silva, William Cárdenas and Adriana Lara. The research is currently in the pre-clinical stage and the clinical phase is planned for the end of 2022 or beginning of 2023.
According to Dr. Bernardo Camacho, director of IDCBIS, "these types of research contributions are fundamental to contribute to improving the health of the country's population". He also explained that this project is part of the consolidation of a research and product development platform that has been developed at the Institute and which has allowed it to be recognized by the Ministry of Science, Technology and Innovation as a Research Center.
Other research conducted by the unit led by Dr. Ingrid Silva includes bioengineering of skin tissue and bone tissue, biological scaffolds for skin regeneration, cell encapsulation for advanced therapy, among others.
13 December, 2021 CellsDonaciónInvestigationNews
The meeting was held on December 9 and brought together the experiences of international donors and the expectations of potential donors to the Colombian program (DarCélulas).
Diciembre, 2021. DarCélulas is a research project executed by the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) with funding from the Science, Technology and Innovation Fund of the General System of Royalties and the District Administration of Bogota.
The purpose of the project is to create the first large database of blood-forming cell donors (also called stem cells), a registry of people willing to save the lives of people who do not know and have diseases such as leukemia.
Registries today exist in many countries around the world such as Japan and the United States; and in Latin America in Mexico, Argentina and Chile, among others. While in Colombia, the creation of the first registry was given in 2019 and with it, the realization of an annual event in which the updated information of the program is shared to the community of registered donors.
The first loyalty event was face-to-face at the Konrad Lorenz University in 2019, where the first balance and perspectives were presented. The 2020 event was virtual and was held with the slogan "compatible with life", in this version it was reported that the program would open its doors to other cities, in addition to Bogota, and experiences of international records were shown.
In the 2021 version, held on December 9, the protagonists were the potential donors who have registered in Colombia, who were the guests of honor at the event; on the other hand, an international story of a donor and a patient who were connected through a donation and were able to meet each other was shown. In addition, the expectations of potential donors who have registered in Bogota, Medellin, Cali and Barranquilla were made known.
At present, the program has surpassed the 3,000 people registered and more than 15,000 pre-registered.
13 December, 2021 InvestigationNewsof Tissue
Dermaglic provides an alternative to improve the quality of scars in patients with sequelae of burns and other traumas.
The skin is the most extensive organ of the human being, when a patient loses it massively there are great complications in the recovery, since only the epidermis has the capacity to regenerate it. When losing all the layers, the skin is reconstructed from collagen with a poor quality of healing, decreasing its function and affecting the aesthetics of patients.
As there are more cases of patients with large and deep burns, the challenge is to improve their quality of life, which is intimately related to the quality of the skin.
A challenge that in the XXI century is faced through tissue engineering with products such as Dermaglic, a class II substitute obtained from glycerolized skin of cadaveric donor which is processed through a chemical process of acceleration where a collagen and elastin sheet is obtained to contribute to the aesthetic and functional improvement of the burn.
Burns are the third cause of traumatic death in the pediatric population worldwide, posing a great challenge for public health that the District Tissue Bank is mitigating by making available to the country's surgeons this innovative alternative in Colombia that will contribute to the treatment of patients to improve the condition of their scars.
"This product that we are making available to patients today to help them in their recovery process is fundamental because it places Colombia at the forefront in the region, Dermaglic being the first of its kind in Latin America," explained Dr. Bernardo Camacho, director of the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) during the launch.
Dr. Alejandro Gomez, Secretary of Health of Bogota, highlighted the work done by the District Tissue Bank for the regeneration of skin of patients who have suffered severe burns and pointed out that the Mayor's Office of Bogota will continue to support the high quality research processes developed at IDCBIS.
The District Tissue Bank is a multi-tissue bank dedicated to donor selection, rescue, processing, preservation, storage and distribution of human tissues for implantation purposes. Currently, the bank processes skin, cornea and sclera, amniotic membrane and musculoskeletal tissue.
PUBLIC INFORMATION
GET INFO
District Institute of Science, Biotechnology and Innovation in Health IDCBIS 2023. All rights reserved
English 
Spanish 